Krystal Biotech, Inc. (KRYS) Key Statistics & Metrics

Krystal Biotech, Inc. (KRYS) has an ST Score of 62.6 out of 100, an overall grade of B. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Wall Street's consensus rating on KRYS is Buy based on 17 analyst ratings. Our own ST Score grades it B (62.6/100). This is data, not investment advice — always do your own research.

Krystal Biotech, Inc. (KRYS) earns a valuation grade of F, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Krystal Biotech, Inc. (KRYS) earns a growth grade of B+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Krystal Biotech, Inc. (KRYS) earns a profitability grade of A+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Krystal Biotech, Inc. (KRYS) earns a financial strength grade of A-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Krystal Biotech, Inc. (KRYS) is $383.75 from 17 analysts, which is +0.1% versus the recent price of $350.88.

Krystal Biotech, Inc. (KRYS) has a Piotroski F-Score of 5 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.